Back
Private Equity
Andrea Alms Video: Money In Motion 101 - Deep Dive - Immunotherapy Cancer Market
March 2024 - Private Equity
- TRANSCRIPT Hello, my name is Andrea Alms. I'm technology investor and financial manager and this is your money emotion. Although we wrapped up on our cancer series on the last episode, I kept thinking about the triple digit multibillion dollar market with double digit growth rate. That's the immunotherapy market. This episode, we take a closer look. Let's review the immunotherapy. Market size is 131.8 billion, with 12.1% growth rate in the category of the largest market size by U.S. dollars.
- Remember, in our last episode, we ranked first place goes to immunotherapy at, you know, the one 31.8 billion in market size and a distant second place is chemotherapy, bone marrow transplant antigen drug conjugate and radiation therapy by drug market immunotherapy. Drug market is segmented into monoclonal antibodies,
- immunomodulators, vaccines and others. It is estimated that monoclonal antibodies has about 42% of the immunotherapy drug market as four key players in 2023 Yahoo Finance article published the top biggest 15 immunotherapy companies in the world.
- Let's start with fifth place AstraZeneca PLC listed on NASDAQ ticker A-Z Market Capitalization 204.39 billion Number of hedge fund holders 42 A Cambridge, UK based pharma biopharmaceutical company that has made significant investment in the areas of immunotherapy and several other promising developments in the field, namely several checkpoint inhibitors, including Envisat and TRIMETHYLAMINE, which has been approved for treatment of several different type of cancers.
- In 2023, AstraZeneca posted an EPS that is earnings per share of a $1.92 U.S. dollars. The company recorded oncology revenue of 17.15 billion. Keep an eye out for AstraZeneca as CAPPIE 02a potential treatment for certain patients with metastatic cancer may be solidify AstraZeneca as a market leader in breast cancer treatment. Fourth place goes to Roche Holdings AG listed on the R.G. Swiss Market cap 202.22 billion U.S. dollars.
- A Basel Switzerland based global company involved in oncology, immunology and other medical research. EPS $15.9 Oncology revenue is 9 billion U.S. dollars. It has expanded its effort to combat crash. That's crass, muted, mutated cancer by securing the rights of Akita Pharma HB 700 and an option to another a renal viral immunotherapy. In exchange, Roche's making an upfront payment of $25 million and pledging up to $930 in potential payments.
- A next episode, we unveiled the top three biggest immunotherapy companies in the world. Thank you. This is your money, your money, in motion.